ROS1 and non-small cell lung carcinoma: ROS1 gene fusion has become a new therapeutic target in patients with advanced or metastatic non‐small‐cell lung cancer (NSCLC) in addition to epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene fusions.